Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $24.1M |
| Operating marginshare of sales left after running the business | -1886.9% |
| Net marginshare of sales kept as profit | -1011.7% |
| Free-cash-flow marginspare cash generated per $100 of sales | -1539.2% |
| Return on invested capitalprofit made on each $100 put into the business | -119.0% |
| Return on equityprofit vs. shareholders' accounting value | -80.8% |
| Change in share countnegative = the company is buying back its shares | +200.0% |
6 insiders sold $394K on the open market.
| Hardiman Roy C.Chief Business & Strategy Ofcr | SoldAug 3 | 2,692 shat $26.37 · $71K |
| Schroer John R.Chief Financial Officer | SoldAug 3 | 3,282 shat $26.37 · $87K |
| Goldstein David MChief Scientific Officer | SoldAug 3 | 2,596 shat $26.37 · $68K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy